Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry.
Nabi H, Hendricks O, Jensen DV, Loft AG, Pedersen JK, Just SA, Danebod K, Munk HL, Kristensen S, Manilo N, Colic A, Linauskas A, Thygesen PH, Christensen LB, Kalisz MH, Lomborg N, Chrysidis S, Raun JL, Andersen M, Mehnert F, Krogh NS, Hetland ML, Glintborg B. Nabi H, et al. Among authors: raun jl. RMD Open. 2022 Nov;8(2):e002560. doi: 10.1136/rmdopen-2022-002560. RMD Open. 2022. PMID: 36418087 Free PMC article.
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.
Glintborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, Danebod K, Jensen DV, Nordin H, Dalgaard EB, Chrysidis S, Kristensen S, Raun JL, Lindegaard H, Manilo N, Jakobsen SH, Hansen IMJ, Dalsgaard Pedersen D, Sørensen IJ, Andersen LS, Grydehøj J, Mehnert F, Krogh NS, Hetland ML. Glintborg B, et al. Among authors: raun jl. Ann Rheum Dis. 2019 Feb;78(2):192-200. doi: 10.1136/annrheumdis-2018-213474. Epub 2018 Nov 5. Ann Rheum Dis. 2019. PMID: 30396903
Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci.
Glintborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, Danebod K, Jensen DV, Nordin H, Dalgaard EB, Chrysidis S, Kristensen S, Raun JL, Lindegaard H, Manilo N, Jakobsen SH, Hansen IMJ, Dalsgaard Pedersen D, Sørensen IJ, Andersen LS, Grydehøj J, Mehnert F, Krogh NS, Hetland ML. Glintborg B, et al. Among authors: raun jl. Ann Rheum Dis. 2020 Feb;79(2):e14. doi: 10.1136/annrheumdis-2018-214788. Epub 2018 Dec 20. Ann Rheum Dis. 2020. PMID: 30573653 No abstract available.
Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries.
Glintborg B, Georgiadis S, Loft AG, Linauskas A, Lindegaard H, Hendricks O, Jensen DV, Andersen BL, Danebod K, Villumsen A, Eng G, Wiell C, Manilo N, Kristensen S, Raun J, Grydehøj J, Chrysidis S, Nørgaard M, Mehnert F, Krogh NS, Hetland ML. Glintborg B, et al. Ann Rheum Dis. 2020 Jun;79(6):846-848. doi: 10.1136/annrheumdis-2019-216702. Epub 2020 Feb 28. Ann Rheum Dis. 2020. PMID: 32111583 No abstract available.
Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
Nabi H, Georgiadis S, Loft AG, Hendricks O, Jensen DV, Andersen M, Chrysidis S, Colic A, Danebod K, Hussein MR, Kalisz MH, Kristensen S, Lomborg N, Manilo N, Munk HL, Pedersen JK, Raun JL, Mehnert F, Krogh NS, Hetland ML, Glintborg B. Nabi H, et al. Among authors: raun jl. Ann Rheum Dis. 2021 Nov;80(11):1400-1409. doi: 10.1136/annrheumdis-2021-219951. Epub 2021 Apr 29. Ann Rheum Dis. 2021. PMID: 33926921
Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.
Jørgensen TS, Kristensen LE, Christensen R, Bliddal H, Lorenzen T, Hansen MS, Østergaard M, Jensen J, Zanjani L, Laursen T, Butt S, Dam MY, Lindegaard HM, Espesen J, Hendricks O, Kumar P, Kincses A, Larsen LH, Andersen M, Næser EK, Jensen DV, Grydehøj J, Unger B, Dufour N, Sørensen V, Vildhøj S, Hansen IM, Raun J, Krogh NS, Hetland ML. Jørgensen TS, et al. Rheumatology (Oxford). 2015 Dec;54(12):2156-65. doi: 10.1093/rheumatology/kev216. Epub 2015 Jul 13. Rheumatology (Oxford). 2015. PMID: 26175471
Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
Glintborg B, Sørensen IJ, Østergaard M, Dreyer L, Mohamoud AA, Krogh NS, Hendricks O, Andersen LS, Raun JL, Kowalski MR, Danielsen L, Pelck R, Nordin H, Pedersen JK, Kraus DG, Christensen SR, Hansen IM, Esbesen J, Schlemmer A, Loft AG, Al Chaer N, Salomonsen L, Hetland ML. Glintborg B, et al. Among authors: raun jl. J Rheumatol. 2017 Jan;44(1):59-69. doi: 10.3899/jrheum.160958. Epub 2016 Dec 1. J Rheumatol. 2017. PMID: 27909080
Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish National Patient Registry.
Ibfelt EH, Sørensen J, Jensen DV, Dreyer L, Schiøttz-Christensen B, Thygesen PH, Colic A, Raun JL, Manilo N, Rødgaard A, Poulsen UE, Rasmussen C, Hansen T, Unger B, Pelck R, Kincses A, Nordin H, Lorenzen T, Theibich A, Jensen Hansen IM, Espesen J, Grydehøj J, Holland-Fischer M, Loft AG, Hetland ML. Ibfelt EH, et al. Among authors: raun jl. Clin Epidemiol. 2017 Nov 29;9:627-632. doi: 10.2147/CLEP.S141438. eCollection 2017. Clin Epidemiol. 2017. PMID: 29238225 Free PMC article.
Response to ''To switch or not to switch': the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al.
Glintborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, Danebod K, Jensen DV, Nordin H, Dalgaard EB, Chrysidis S, Kristensen S, Raun JL, Lindegaard H, Manilo N, Jakobsen SH, Hansen IMJ, Pedersen DD, Sørensen IJ, Andersen LS, Grydehøj J, Mehnert F, Krogh NS, Lund Hetland M. Glintborg B, et al. Among authors: raun jl. Ann Rheum Dis. 2020 Apr;79(4):e37. doi: 10.1136/annrheumdis-2018-214952. Epub 2019 Jan 23. Ann Rheum Dis. 2020. PMID: 30674476 No abstract available.
A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial.
Axelsen MB, Eshed I, Hørslev-Petersen K, Stengaard-Pedersen K, Hetland ML, Møller J, Junker P, Pødenphant J, Schlemmer A, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Dam MY, Hansen I, Horn HC, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Krogh NS, Johansen JS, Østergaard M; OPERA study group. Axelsen MB, et al. Ann Rheum Dis. 2015 May;74(5):867-75. doi: 10.1136/annrheumdis-2013-204537. Epub 2014 Jan 10. Ann Rheum Dis. 2015. PMID: 24412895 Clinical Trial.
15 results